Edition:
United States

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

4,210JPY
2:00am EDT
Change (% chg)

¥-25 (-0.59%)
Prev Close
¥4,235
Open
¥4,210
Day's High
¥4,235
Day's Low
¥4,200
Volume
576,600
Avg. Vol
1,021,466
52-wk High
¥4,270
52-wk Low
¥3,010

Latest Key Developments (Source: Significant Developments)

Chugai Pharmaceutical sells trusted beneficial rights of property
Friday, 12 May 2017 03:01am EDT 

May 12 (Reuters) - Chugai Pharmaceutical Co Ltd <1491.T>: :* Says it has sold the trusted beneficial rights of Tokyo-based property on May 12.  Full Article

Baxalta files lawsuit against Chugai Pharmaceutical and Genentech
Wednesday, 10 May 2017 11:03pm EDT 

May 11(Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Baxalta filed a lawsuit against the company and Genentech Inc., in U.S. on May 4.Says the lawsuit is mainly for a judgment for an injunction against infringement of patent right.  Full Article

Chugai Pharmaceutical to issue 123,000 shares for 469.9 mln yen
Thursday, 23 Mar 2017 04:05am EDT 

Chugai Pharmaceutical Co Ltd <4519.T>:Says it plans to issue 123,000 shares for 469.9 million yen in total.  Full Article

Pharma Mar signs licensing deal with Chugai Pharmaceutical for PM1183 in Japan
Thursday, 22 Dec 2016 01:58am EST 

Pharma Mar SA : Signs exclusive licensing and marketing agreement with Chugai Pharmaceutical Co. Ltd. for PM1183 in Japan . Says will receive an initial payment of 30 million euros ($31.33 million) and royalties .May get other payments depending on whether certain milestones are met, both for clinical development and sales, of over 100 million euros in total.  Full Article

R&I affirms Chugai Pharmaceutical's rating at "AA-" and announces stable outlook – R&I
Thursday, 8 Dec 2016 01:15am EST 

Chugai Pharmaceutical Co Ltd <4519.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" – R&I .Rating outlook stable– R&I.  Full Article

Chugai and Galderma announce global license agreement for Nemolizumab
Wednesday, 20 Jul 2016 07:30pm EDT 

Chugai Pharmaceutical Co Ltd <4519.T>: Chugai will continue to be responsible for product manufacturing and supply of Nemolizumab. . Under terms of agreement, Chugai will receive an upfront, milestone and royalty payments from Galderma. . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases .Chugai will grant Galderma license for development and marketing of nemolizumab worldwide, exception of Japan and Taiwan.  Full Article

Chugai Pharmaceutical says concluded a license agreement with Roche
Wednesday, 1 Jun 2016 02:00am EDT 

Chugai Pharmaceutical Co Ltd: Announced that it concluded a license agreement with roche for "sa237" .Per the terms of the agreement, chugai will receive an upfront fee, milestone and royalty payments from roche..  Full Article

Six Japanese drugmakers will team up to discover new cancer, depression treatments - Nikkei
Wednesday, 25 May 2016 01:22pm EDT 

Nikkei: Astellas Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharmaceutical,Chugai Pharmaceutical will collaborate with 4 research institutions - Nikkei . The Six Drugmakers will work with research organizations providing cell, tissue samples to discover new pharmaceuticals - Nikkei . Around 3 billion Yen ($27.2 Million) will be put into drug-discovery efforts by fiscal 2019 - Nikkei .Group will create five teams looking into treatments for cancer, diabetic nephropathy and mental illnesses including depression - Nikkei.  Full Article

Chugai Pharmaceutical announces results of Japanese phase III study of Alecensa
Wednesday, 18 May 2016 09:25pm EDT 

Chugai Pharmaceutical Co Ltd : Announced results of Japanese phase III study of Alecensa in Alk fusion gene positive non-small cell lung cancer .PFS hazard ratio of Alecensa arm to Crizotinib arm was 0.34 and Alecensa demonstrated significantly prolonged PFS.  Full Article

Chugai Pharmaceutical wins Patent-Infringement lawsuit regarding OXAROL® Ointment
Friday, 25 Mar 2016 03:00am EDT 

Chugai Pharmaceutical Co Ltd:Wins a lawsuit filed by the company against companies which manufacturing and marketing their generic drugs in infringement of the process patent on "OXAROL® Ointment 25 μg/g", a Chugai's drug for treatment of keratosis including psoriasis vulgaris, on March 25.Says the grand panel judgment made by the Special Division of the Intellectual Property High Court was to reject the appeal by the generic companies, and by which, Chugai's claim was fully supported.  Full Article

More From Around the Web

BRIEF-Chugai Pharmaceutical sells trusted beneficial rights of property

* Says it has sold the trusted beneficial rights of Tokyo-based property on May 12